<DOC>
	<DOCNO>NCT02920710</DOCNO>
	<brief_summary>There need reliable , expeditious therapy use alternative glucocorticoid severe Central Nervous System ( CNS ) sarcoidosis . This study aim provide evidence effectiveness ACTHAR gel CNS sarcoidosis , provide information safety tolerability</brief_summary>
	<brief_title>ACTHAR Therapy Central Nervous System Sarcoidosis</brief_title>
	<detailed_description>Central nervous system ( CNS ) involvement one severe manifestation sarcoidosis . Sarcoidosis affect leptomeninges , spinal cord , brain parenchyma portend difficult course frequently result severe disability death ( 1 ) . Treatment moderate severe CNS sarcoidosis typically involve combination corticosteroid cytotoxic agent methotrexate ( 2 ) . Unfortunately , response rate reportedly 29-38 % range corticosteroid alone , effect cytotoxic agent sarcoidosis require 6 month occur . A typical scenario patient treat prolonged period high dose glucocorticoid suboptimal effectiveness despite development substantial toxicity . Some series report cyclophosphamide infliximab may beneficial ( 3 ) , approaches limit potentially severe toxicity , loss effectiveness , payor constraint . . ACTHAR 39-amino acid peptide natural form adrenocorticotropin hormone ( ACTH ) initially approved 1952 FDA . It since approve 19 indication include respiratory sarcoidosis , multiple sclerosis , infantile spasm .</detailed_description>
	<mesh_term>Sarcoidosis</mesh_term>
	<mesh_term>Central Nervous System Diseases</mesh_term>
	<mesh_term>Adrenocorticotropic Hormone</mesh_term>
	<criteria>Patient sarcoidosis define ATS/ERS/WASOG ( American Thoracic Society/European Thoracic Society/World Association Sarcoidosis Other Granulomatous Disorders ) Stable baseline immunosuppressive medication Moderate severe disease define least one follow criterion : Cranial nerve palsy Neurologic deficit relate intraparenchymal brain , spinal cord and/or cauda equina involvement Dural leptomeningeal involvement brain and/or spinal cord Hydrocephalus Seizures Diagnosis underlie neurologic disorder would potentially confound interpretation study result Significant change corticosteroid dose within past 4 week , immunosuppressive medication within past 6 month Evidence current serious infection , history chronic recur infection . Contraindication highdose corticosteroid ( e.g . uncontrolled blood sugar ) . Allergies pigderived protein Have history opportunistic infection within 6 month prior screen History malignancy .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>